7,082,491 Shares in Personalis, Inc. $PSNL Bought by BlackRock Inc.

Key Points

• BlackRock acquired 7.08 million Personalis shares worth approximately $94.9 million, giving it a 6.76% stake. Institutional investors and hedge funds collectively own 61.91% of the company.
• Analyst sentiment is mixed, with four Buy, four Hold, and two Sell ratings. Personalis has an average rating of Hold and a consensus price target of $14.54.
• Personalis reported quarterly revenue of $22.36 million, exceeding estimates, but its adjusted loss of $0.30 per share missed expectations. Insiders sold 296,233 shares worth $4.05 million over the past 90 days.

BlackRock Inc. purchased a new position in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,082,491 shares of the company's stock, valued at approximately $94,905,000. BlackRock Inc. owned about 6.76% of Personalis at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd raised its holdings in shares of Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company's stock valued at $27,000 after buying an additional 1,479 shares during the period. Deutsche Bank AG grew its stake in shares of Personalis by 4.5% during the fourth quarter. Deutsche Bank AG now owns 38,827 shares of the company's stock valued at $309,000 after acquiring an additional 1,655 shares in the last quarter. Royal Bank of Canada grew its stake in shares of Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company's stock valued at $275,000 after acquiring an additional 2,395 shares in the last quarter. Howland Capital Management LLC increased its position in shares of Personalis by 0.9% during the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company's stock worth $1,872,000 after acquiring an additional 2,500 shares during the last quarter. Finally, Intech Investment Management LLC increased its position in shares of Personalis by 23.4% during the fourth quarter. Intech Investment Management LLC now owns 20,342 shares of the company's stock worth $162,000 after acquiring an additional 3,851 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company's stock.

Analyst Ratings Changes

PSNL has been the subject of several recent analyst reports. Craig Hallum lowered shares of Personalis from a "buy" rating to a "hold" rating and set a $16.25 price objective for the company. in a report on Monday, August 24th. Wall Street Zen lowered shares of Personalis from a "hold" rating to a "sell" rating in a research note on Saturday, June 13th. Needham & Company LLC downgraded Personalis from a "buy" rating to a "hold" rating in a research note on Monday, July 20th. Lake Street Capital lowered Personalis from a "buy" rating to a "hold" rating and set a $16.25 price objective for the company. in a report on Monday, July 20th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Personalis in a report on Wednesday, July 15th. Four research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Personalis currently has an average rating of "Hold" and a consensus target price of $14.54.

Insider Activity

In other Personalis news, CFO Aaron Tachibana sold 4,982 shares of the business's stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $14.00, for a total transaction of $69,748.00. Following the sale, the chief financial officer directly owned 198,833 shares in the company, valued at approximately $2,783,662. The trade was a 2.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the company's stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the completion of the sale, the chief executive officer directly owned 235,986 shares of the company's stock, valued at approximately $3,558,668.88. This represents a 29.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 296,233 shares of company stock valued at $4,048,636 in the last ninety days. Corporate insiders own 4.20% of the company's stock.

Personalis Price Performance

PSNL opened at $17.07 on Friday. The stock's 50 day moving average price is $14.00 and its 200 day moving average price is $9.98. The stock has a market cap of $1.79 billion, a P/E ratio of -15.66 and a beta of 2.27. Personalis, Inc. has a 12 month low of $4.65 and a 12 month high of $18.89.

Personalis (NASDAQ:PSNL - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The business had revenue of $22.36 million during the quarter, compared to the consensus estimate of $16.69 million. Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. Equities analysts anticipate that Personalis, Inc. will post -1.07 EPS for the current year.

About Personalis

Personalis, Inc NASDAQ: PSNL is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

Want to see what other hedge funds are holding PSNL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Personalis, Inc. (NASDAQ:PSNL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source